Yes, ferrous sulfate can be safely given to a child with G6PD deficiency who has anemia.
Ferrous sulfate is NOT contraindicated in G6PD deficiency and can be administered safely for iron deficiency anemia in children with this condition. The concern about G6PD deficiency relates to oxidative stress-inducing medications that trigger hemolysis, but iron supplementation itself does not cause this problem.
Evidence-Based Rationale
G6PD Deficiency and Medication Safety
A comprehensive evidence-based review of medications in G6PD deficiency identified only seven medications with solid evidence to prohibit their use: dapsone, methylthioninium chloride (methylene blue), nitrofurantoin, phenazopyridine, primaquine, rasburicase, and tolonium chloride 1. Ferrous sulfate is notably absent from this list, and the review explicitly states that for all other medications not on this prohibited list, no evidence contraindicates their use in normal therapeutic doses for G6PD-deficient patients 1.
Iron Supplementation in Children
For pediatric iron deficiency anemia, ferrous sulfate remains the first-line oral iron therapy. A randomized clinical trial in children aged 9-48 months demonstrated that low-dose ferrous sulfate (3 mg/kg once daily) effectively increased hemoglobin from 7.9 to 11.9 g/dL over 12 weeks, with superior efficacy compared to iron polysaccharide complex 2. The study showed 29% complete resolution of IDA with ferrous sulfate 2.
Additional pediatric studies confirm ferrous sulfate's safety and efficacy profile in young children, with one open-label trial showing normalization of hemoglobin in 95% of children aged 6-53 months using 2 mg/kg/day dosing 3.
Clinical Approach
Dosing Recommendations
- Standard dose: 3 mg/kg of elemental iron once daily 2
- Alternative dose: 2 mg/kg/day has also shown efficacy 3
- Duration: Continue for approximately 3 months after hemoglobin normalization to replenish iron stores 4
Monitoring Strategy
- Check hemoglobin response within the first 4 weeks 4
- Monitor iron status parameters (hemoglobin, ferritin) regularly 3
- In G6PD-deficient children, also monitor for signs of hemolysis if concurrent infections or other oxidative stressors are present
Important Caveats
The Real Concern in G6PD Deficiency
The primary risk in G6PD-deficient patients is hemolysis triggered by oxidative stress, which commonly occurs during:
- Acute infections (the most common trigger)
- Exposure to the seven prohibited medications listed above
- Consumption of fava beans (in certain G6PD variants)
Iron deficiency itself does not trigger hemolysis in G6PD deficiency. In fact, many G6PD-deficient children develop iron deficiency anemia from chronic hemolytic episodes and require iron supplementation.
Avoid Confusion
Historical medical literature incorrectly attributed hemolysis to various medications when patients were actually experiencing infection-related hemolytic episodes 1. This has led to unnecessary medication restrictions that lack evidence-based support.
Alternative Iron Formulations
If ferrous sulfate is not tolerated due to gastrointestinal side effects (unrelated to G6PD status):
- Ferrous gluconate is equally effective 5, 6
- Reduce dosing to alternate-day administration 4
- Consider parenteral iron for severe intolerance (though enteral route is preferred when tolerated) 7
The bottom line: Treat the iron deficiency anemia with standard ferrous sulfate therapy; the G6PD deficiency does not change this management.